Article Figures & Data
Figures
- Figure 1
- Data collection process.
Tables
Demographics categories n (%) Gender Male 124 (82.2) Female 27 (17.8) Age 16-30 34 (22.5) 31-50 65 (43.1) 51-70 35 (23.2) 70 and more 17 (11.2) Level of injury Paraplegia 105 (69.5) Tetraplegia 45(29.8) Cauda Equina Syndrome 1 (0.7) Voiding method Self-intermittent catheterization 64 (42.3) Indwelling Foley catheter 39 (25.8) Free voiding 29 (19.2) Suprapubic catheter 15 (10) Condom catheter 4 (2.7) Organisms by voiding methods Freely Condom Catheter Foley catheter Self-intermittent catheterization Suprapubic catheter Total Acinetobacter Baumanii 2 (33.4) 0 0 3 (50) 1 (16.7) 6 (1.2) Citrobacter Koseri 0 0 0 2 (66.7) 1 (33.3) 3 (0.6) Citrobacter Freundii 0 0 1 (16.7) 4 (66.7) 1 (16.7) 6 (1.2) Enterobacter Cloacae 5 (35.7) 0 3 (21.4) 4 (28.6) 2 (14.3) 14 (2.8) Enterococcus Aerogens 0 0 0 1 (100) 0 1 (0.2) Enterococcus Faecalis 3 (12.5) 0 4 (16.7) 13 (54.2) 4 (16.7) 24 (4.8) Enterococcus Faecium 0 0 0 1 (100) 0 1 (0.2) Escherichia Coli 16 (11) 4 (2.7) 36 (24.7) 68 (46.6) 22 (15.1) 146 (29.3) Escherichia Coli (ESBL*) 6 (27.3) 0 0 15 (68.2) 1 (4.5) 22 (4.4) Klebsiella Oxytoca 0 0 0 1 (50) 1 (50) 2 (0.4) Klebsiella Pnumoniae 21 (20.8) 0 11 (10.9) 56 (55.4) 13 (12.9) 101 (20.2) Klebsiella Pnumoniae(ESBL*) 1 (12.5) 0 0 7 (87.5) 0 8 (1.6) Morganella Morganii 0 0 2 (22.2) 5 (55.6) 2 (22.2) 9(1.8) Proteus Mirabilis 11 (16.7) 0 13 (19.7) 20 (30.3) 22 (33.3) 66 (13.2) Proteus Mirabilis (MDR**) 0 0 1 (25) 3 (75) 0 4 (0.8) Providencia Stuartii 0 0 2 (15.4) 9 (69.2) 2 (15.4) 13(2.6) Providencia Stuartii (MDR**) 1 (14.3) 0 6 (85.7) 0 0 7 (1.4) Pseudomonas Aeruginosa 2 (3.4) 1 (1.7) 20 (34.5) 27 (46.6) 8 (13.8) 58 (11.6) Pseudomonas Aeruginosa(MDR**) 0 0 1 (50) 1 (50) 0 2 (0.4) Serratia Marcescens 0 0 0 1 (100) 0 1 (0.2) Staphylococcus Aureus 0 0 1 (50) 1 (50) 0 2 (0.4) Staphylococcus Aureus (MRSA***) 0 0 0 2 (66.7) 1 (33.3) 3 (0.6) Total 68 (13.6) 5 (1) 101 (20.2) 244 (48.%) 81 (16.2) 499 (100) Antibiotic by voiding methods Freely Condom catheter Foley catheter Self-intermittent catheterization Suprapubic catheter Total Amikacin 11 (12.6) 0 14 (16.1) 45 (51.7) 17 (19.5) 87 (17.4) Ampilicin 12 (15.6) 0 12 (15.6) 37 (48.1) 16 (20.8) 77 (15.4) Augmentin 23 (13.8) 2 (1.2) 33 (19.8) 83 (49.7) 26 (15.6) 167 (33.5) Azithromycin 1 (100) 0 0 0 0 1 (0.2) Ciprofloxacin 12 (7.6) 2 (1.3) 33 (21) 83 (52.9) 27 (17.2) 157 (31.5) Ceftazidime 3 (5.3) 1 (1.8) 19 (33.3) 24 (42.1) 10 (17.5) 57 (11.4) Cefazolin 1 (100) 0 0 0 0 1 (0.2) Cefuroxime 25 (15.8) 4 (2.5) 34 (21.5) 71 (44.9) 24 (15.2) 158 (31.7) Cefotaxime 1 (5.6) 0 3 (16.7) 12 (66.7) 2 (11.1) 18 (3.6) Cefipime 1 (8.3) 0 2 (16.7) 7 (58.3) 2 (16.7) 12 (2.4) Colistin 5 (17.9) 0 6 (21.4) 13 (46.4) 4 (14.3) 28 (5.6) Chloramphenicol 1 (100) 0 0 0 0 1 (0.2) Clindamycin 0 0 0 1 (100) 0 1 (0.2) Ertapanem 8 (12.5) 0 7 (10.9) 36 (56.2) 13 (20.3) 64 (12.8) Erythromycin 0 0 0 1 (100) 0 1 (0.2) Fosfomycin 1 (2.8) 0 4 (11.1) 24 (66.7) 7 (19.4) 36 (7.2) Flucloxacillin 0 0 1 (33.3) 2 (66.7) 0 3 (0.6) Imipenem 11 (13.4) 0 14 (17.1) 45 (54.9) 12 (14.6) 82 (16.4) Gentamicin 34 (15.5) 3 (1.4) 47 (21.4) 111 (50.5) 25 (11.4) 220 (44.1) Levofloxacin 1 (14.3) 0 2 (28.6) 2 (28.6) 2 (28.6) 7 (1.4) Meropenem 13 (16) 0 16 (19.8) 37 (45.7) 15 (18.5) 81 (16.2) Nalidixic Acid 1 (50) 0 1 (50) 0 0 2 (0.4) Nitrofurantoin 25 (12.8) 4 (2.1) 36 (18.5) 103 (52.8) 27 (13.8) 195 (39.1) Norfloxacin 14 (16.7) 3 (3.6) 17 (20.2) 37 (44) 13 (15.5) 84 (16.8) Trimethoprim /Sulfamethoxazole 23 (14.6) 2 (1.3) 25 (15.9) 89 (56.7) 18 (11.5) 157 (31.5) Tazocin 4 (4.9) 1 (1.2) 21 (25.6) 41 (50) 15 (18.3) 82 (16.4) Tetracycline 1 (33.3) 0 0 1 (33.3) 1 (33.3) 3 (0.6) Tigecycline 2 (40) 0 1 (20) 2 (40) 0 5 (1) Tobramycin 1 (50) 0 1 (50) 0 0 2 (0.4) Trimethoprim 4 (50) 0 1 (12.5) 3 (37.5) 0 8 (1.6) Vancomycin 3 (20) 0 2 (13.3) 7 (46.7) 3 (20) 15 (3) Total 68 (13.6) 5 (1) 101 (20.2) 244 (48.9) 81 (16) 499 (100)
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.